Dr Nigel Jamieson

  • Senior Clinical Lecturer (Institute of Cancer Sciences)

Biography

Nigel Jamieson is a Clinical Senior Lecturer within the Institute of Cancer Sciences and an Honorary HPB surgeon at Glasgow Royal Infirmary. He completed his undergraduate medical degree at the University of Glasgow when his interest in pancreatic cancer research began. He subsequently undertook a PhD funded by the Chief Scientist Office investigating gene expression signatures in pancreatic adenocarcinoma at the Beatson Institute. After completing his surgical training including observership periods at Johns Hopkins, Baltimore and Memorial Sloan Kettering Cancer Center, New York he undertook an international fellowship year of pancreas and liver surgery in Royal North Shore Hospital, Sydney, Australia where he gained significant experience in post-neoadjuvant therapy pancreatic resections. Grants from the Academy of Sciences and Pancreatic Cancer UK maintained his research output during his surgical training. He was recently awarded a Clinician Scientist Fellowship by Cancer Research UK and upon returning to Glasgow was awarded a Lord Kelvin and Adam Smith Leadership Fellowship from the University of Glasgow.

He has contributed to over 70 peer reviewed publications and with an active role in the development and management of the Precision-Panc platform, his primary research interest now focusses upon the interaction between the genomic landscape, the immune microenvironment and chemotherapy in patients with pancreatic cancer. Specifically, he will look to develop combination therapeutic strategies that target Immune evasion in pancreatic cancer.


Publications

List by: Type | Date

Jump to: 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2006 | 2005 | 2004 | 2003
Number of items: 81.

2019

Pulvirenti, A. et al. (2019) Multi-institutional development and external validation of a nomogram to predict recurrence after curative resection of pancreatic neuroendocrine tumors. Annals of Surgery, (doi:10.1097/SLA.0000000000003579) (PMID:31567347) (Early Online Publication)

Dreyer, S.B., Jamieson, N.B. , Morton, J.P. , Sansom, O.J. , Biankin, A.V. and Chang, D.K. (2019) Pancreatic cancer: from genome discovery to PRECISION-Panc. Clinical Oncology, (doi:10.1016/j.clon.2019.08.007) (PMID:31522943) (In Press)

Vennin, C. et al. (2019) CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nature Communications, 10, 3637. (doi:10.1038/s41467-019-10968-6) (PMID:31406163) (PMCID:PMC6691013)

Dreyer, S.B., Jamieson, N.B. , Cooke, S.L. , Valle, J.W., McKay, C.J., Biankin, A.V. and Chang, D.K. (2019) PRECISION-Panc: the next generation therapeutic development platform for pancreatic cancer. Clinical Oncology, (doi:10.1016/j.clon.2019.07.011) (PMID:31378449) (In Press)

Reader, C. S. et al. (2019) The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Journal of Pathology, (doi:10.1002/path.5320) (PMID:31259422) (Early Online Publication)

Seykora, T. F. et al. (2019) The beneficial effects of minimizing blood loss in pancreatoduodenectomy. Annals of Surgery, 270(1), pp. 147-157. (doi:10.1097/SLA.0000000000002714) (PMID:29489483)

Janssen, Q. P. et al. (2019) Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. Journal of the National Cancer Institute, (doi:10.1093/jnci/djz073) (PMID:31086963) (Early Online Publication)

Dreyer, S. B. et al. (2019) Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. Chinese Clinical Oncology, 8(2), 16. (doi:10.21037/cco.2019.04.06) (PMID:31070037)

Singh, G., Nahm, C. B., Jamieson, N. B. , Chua, T. C., Wong, S., Thoo, C., Mittal, A., Gill, A. J. and Samra, J. S. (2019) Management of post-pancreatectomy haemorrhage using resuscitative endovascular balloon occlusion of the aorta. Langenbeck's Archives of Surgery, 404(2), pp. 253-255. (doi:10.1007/s00423-019-01759-0) (PMID:30758668)

Strijker, M., Chen, J.W., Mungroop, T.H., Jamieson, N.B. , van Eijck, C.H., Steyerberg, E.W., Wilmink, J.W., Groot Koerkamp, B., van Laarhoven, H.W. and Besselink, M.G. (2019) Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer. British Journal of Surgery, 106(4), pp. 342-354. (doi:10.1002/bjs.11111) (PMID:30758855)

Maggino, L. et al. (2019) Identification of an optimal cut-off for drain fluid amylase on postoperative day 1 for predicting clinically relevant fistula after distal pancreatectomy. Annals of Surgery, 269(2), pp. 337-343. 28938266. (doi:10.1097/SLA.0000000000002532)

Nahm, C. B. et al. (2019) Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: a multi-institutional cohort study. European Journal of Surgical Oncology, 45(2), pp. 218-224. (doi:10.1016/j.ejso.2018.10.050) (PMID:30348604)

Moekotte, A. L. et al. (2019) Histopathologic predictors of survival and recurrence in resected ampullary adenocarcinoma. Annals of Surgery, (doi:10.1097/SLA.0000000000003177) (PMID:30628913) (Early Online Publication)

Ecker, B. L. et al. (2019) Risk factors and mitigation strategies for pancreatic fistula after distal pancreatectomy. Annals of Surgery, 269(1), pp. 143-149. (doi:10.1097/SLA.0000000000002491) (PMID:28857813)

2018

Dreyer, S. B. et al. (2018) Precision oncology in surgery: patient selection for operable pancreatic cancer. Annals of Surgery, (doi:10.1097/SLA.0000000000003143) (PMID:30570546) (Early Online Publication)

Ecker, B. L. et al. (2018) Characterization and optimal management of high-risk pancreatic anastomoses during pancreatoduodenectomy. Annals of Surgery, 267(4), pp. 608-616. (doi:10.1097/SLA.0000000000002327) (PMID:28594741)

Dreyer, S.B., Jamieson, N.B. , Upstill-Goddard, R., Bailey, P.J. , McKay, C.J., Australian Pancreatic Cancer Genome Initiative, , Biankin, A.V. and Chang, D.K. (2018) Defining the molecular pathology of pancreatic body and tail adenocarcinom. British Journal of Surgery, 105(2), e183-e191. (doi:10.1002/bjs.10772) (PMID:29341146) (PMCID:PMC5817249)

Ecker, B. L. et al. (2018) Pancreatogastrostomy vs. pancreatojejunostomy: a risk-stratified analysis of 5316 pancreatoduodenectomies. Journal of Gastrointestinal Surgery, 22(1), pp. 68-76. (doi:10.1007/s11605-017-3547-2) (PMID:28840459)

2017

Balachandran, V. P. et al. (2017) Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 551, pp. 512-516. (doi:10.1038/nature24462) (PMID:29132146)

Scarpa, A. et al. (2017) Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 550(7677), p. 548. (doi:10.1038/nature24026) (PMID:28953865)

Grose, D. et al. (2017) The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. Journal of Gastrointestinal Oncology, 8(4), pp. 683-695. (doi:10.21037/jgo.2017.04.01) (PMID:28890819) (PMCID:PMC5582039)

Johns, A. L. et al. (2017) Lost in translation: returning germline genetic results in genome-scale cancer research. Genome Medicine, 9, 41. (doi:10.1186/s13073-017-0430-4) (PMID:28454591) (PMCID:PMC5408494)

Scarpa, A. et al. (2017) Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 543(7643), pp. 65-71. (doi:10.1038/nature21063) (PMID:28199314)

Jamieson, N.B. and Maker, A.V. (2017) Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Therapy, 24(3), pp. 134-140. (doi:10.1038/cgt.2016.63) (PMID:27834354)

Humphris, J. L. et al. (2017) Hypermutation in pancreatic cancer. Gastroenterology, 152(1), 68-74.e2. (doi:10.1053/j.gastro.2016.09.060) (PMID:27856273)

2016

Steele, C. W. et al. (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell, 29(6), pp. 832-845. (doi:10.1016/j.ccell.2016.04.014) (PMID:27265504) (PMCID:PMC4912354)

Palani Velu, L.K., McKay, C.J., Carter, C.R., McMillan, D.C. , Jamieson, N.B. and Dickson, E.J. (2016) Serum amylase and C-reactive protein in risk stratification of pancreas-specific complications after pancreaticoduodenectomy. British Journal of Surgery, 103(5), pp. 553-563. (doi:10.1002/bjs.10098) (PMID:26898605)

Bailey, P. et al. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531(7592), pp. 47-52. (doi:10.1038/nature16965) (PMID:26909576)

Gingras, M.-C. et al. (2016) Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation. Cell Reports, 14(4), pp. 907-919. (doi:10.1016/j.celrep.2015.12.005) (PMID:26804919) (PMCID:PMC4982376)

Ali, A. et al. (2016) Investigating various thresholds as immunohistochemistry cutoffs for observer agreement. Applied Immunohistochemistry and Molecular Morphology, 25(9), pp. 599-608. (doi:10.1097/PAI.0000000000000357) (PMID:27093449)

2015

Palani Velu, L., Chandrabalan, V., McMillan, D. , McKay, C., Carter, C. R., Jamieson, N. and Dickson, E. (2015) Routine drainage after pancreaticoduodenectomy. Annals of Surgery, 262(6), e107. (doi:10.1097/sla.0000000000000758) (PMID:24887980)

Jamieson, N. B. , Chang, D. K. and Biankin, A. V. (2015) Cancer genetics and implications for clinical management. Surgical Clinics of North America, 95(5), pp. 919-934. (doi:10.1016/j.suc.2015.05.003) (PMID:26315514)

Graham, J., Jamieson, N.B. , Rulach, R., Grimmond, S.M., Chang, D.K. and Biankin, A.V. (2015) Pancreatic cancer genomics: where can the science take us? Clinical Genetics, 88(3), pp. 213-219. (doi:10.1111/cge.12536) (PMID:25388820)

Palani Velu, L. K., Steele, C. W. , Dickson, E., Carter, C. R., McKay, C. J., Horgan, P. G. , McMillan, D. C. and Jamieson, N. B. (2015) RE:nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. Journal of the National Cancer Institute, 107(9), djv204. (doi:10.1093/jnci/djv204) (PMID:26251329)

Frampton, A. E. et al. (2015) microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: a meta-analysis. European Journal of Cancer, 51(11), pp. 1389-1404. (doi:10.1016/j.ejca.2015.04.006) (PMID:26002251)

McGlynn, L. M., McCluney, S., Jamieson, N. B. , Thomson, J., MacDonald, A. I., Oien, K. , Dickson, E. J., Carter, C. R., McKay, C. J. and Shiels, P. G. (2015) SIRT3 & SIRT7: potential novel biomarkers for determining outcome in pancreatic cancer patients. PLoS ONE, 10(6), e0131344. (doi:10.1371/journal.pone.0131344) (PMID:26121130) (PMCID:PMC4487247)

Solaini, L., Jamieson, N.B. , Metcalfe, M., Abu Hilal, M., Soonawalla, Z., Davidson, B.R., McKay, C. and Kocher, H.M. (2015) Outcome after surgical resection for duodenal adenocarcinoma in the UK. British Journal of Surgery, 102(6), pp. 676-681. (doi:10.1002/bjs.9791) (PMID:25776995)

Waddell, N. et al. (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), pp. 495-501. (doi:10.1038/nature14169) (PMID:25719666) (PMCID:PMC4523082)

Maker, A. V., Carrara, S., Jamieson, N. B. , Pelaez-Luna, M., Lennon, A. M., Dal Molin, M., Scarpa, A., Frulloni, L. and Brugge, W. R. (2015) Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: A critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. Journal of the American College of Surgeons, 220(2), pp. 243-253. (doi:10.1016/j.jamcollsurg.2014.11.001) (PMID:25592469) (PMCID:PMC4304635)

Rainero, E., Howe, J. D., Caswell, P. T., Jamieson, N. B. , Anderson, K., Critchley, D. R., Machesky, L. and Norman, J. C. (2015) Ligand-occupied integrin internalization links nutrient signaling to invasive migration. Cell Reports, 10(3), pp. 398-413. (doi:10.1016/j.celrep.2014.12.037)

Miller, B. W. et al. (2015) Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine, 7, pp. 1063-1076. (doi:10.15252/emmm.201404827) (PMID:26077591) (PMCID:PMC4551344)

2014

Lunardi, S. et al. (2014) IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. Oncotarget, 5(22), pp. 11064-11080. (doi:10.18632/oncotarget.2519) (PMID:25415223) (PMCID:PMC4294325)

Steele, C. W., Jamieson, N. B. and Carter, C. R. (2014) Inflammatory dysregulation and cancer: From molecular mechanisms to therapeutic opportunities. In: Wondrak, G. T. (ed.) Stress Response Pathways in Cancer. Springer, pp. 375-395. ISBN 9789401794206 (doi:10.1007/978-94-017-9421-3_17)

Morran, D. C. et al. (2014) Targeting mTOR dependency in pancreatic cancer. Gut, 63(9), pp. 1481-1489. (doi:10.1136/gutjnl-2013-306202) (PMID:24717934) (PMCID:PMC4145424)

Hamilton, G. et al. (2014) AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget, 5(15), pp. 6142-6167. (doi:10.18632/oncotarget.2178) (PMID:25071014) (PMCID:PMC4171619)

Palani Velu, L. K., Chandrabalan, V. V., Jabbar, S., McMillan, D. C. , McKay, C. J., Carter, C. R., Jamieson, N. B. and Dickson, E. J. (2014) Serum amylase on the night of surgery predicts clinically significant pancreatic fistula after pancreaticoduodenectomy. HPB, 16(7), pp. 610-619. (doi:10.1111/hpb.12184) (PMID:24246024)

Jamieson, N. B. , Chang, D. K. , Grimmond, S. M. and Biankin, A. V. (2014) Can we move towards personalised pancreatic cancer therapy? Expert Review of Gastroenterology and Hepatology, 8(4), pp. 335-338. (doi:10.1586/17474124.2014.893820) (PMID:24702631)

Li, A. et al. (2014) Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. Gastroenterology, 146(5), 1386-1396.e17. (doi:10.1053/j.gastro.2014.01.046)

Frampton, A. E., Giovannetti, E., Jamieson, N. B. , Krell, J., Gall, T. M.H., Stebbing, J., Jiao, L. R. and Castellano, L. (2014) A microRNA meta-signature for pancreatic ductal adenocarcinoma. Expert Review of Molecular Diagnostics, 14(3), pp. 267-271. (doi:10.1586/14737159.2014.893192)

Roxburgh, C.S. et al. (2014) A national survey of attitudes to research in Scottish General Surgery Trainees. Scottish Medical Journal, 59(1), pp. 9-15. (doi:10.1177/0036933013518142) (PMID:24434857)

Ali, A. et al. (2014) Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel. BMC Clinical Pathology, 14, p. 35. (doi:10.1186/1472-6890-14-35)

Chang, D. K. , Jamieson, N. B. , Grimmond, S. M. and Biankin, A. V. (2014) Stratified medicine for pancreatic cancer. In: Padmanabhan, S. (ed.) Handbook of Pharmacogenomics and Stratified Medicine. Elsevier, pp. 807-814. ISBN 9780123868824 (doi:10.1016/B978-0-12-386882-4.00034-7)

Jamieson, N. B. , Grimmond, S. M., Biankin, A. V. and Chang, D. K. (2014) Pancreatic cancer: Challenges for therapeutic development. In: Scarlett, C. J. and Vuong, Q. V. (eds.) Plant Bioactive Compounds for Pancreatic Cancer Prevention and Treatment. Nova Science, pp. 1-28. ISBN 9781634633246

2013

Chang, D. K. , Jamieson, N. B. , Scarpa, A., McKay, C. J. and Biankin, A. V. (2013) Reply to G.F. Arroyo. Journal of Clinical Oncology, 31(30), pp. 3843-3844. (doi:10.1200/JCO.2013.51.3176) (PMID:24043730)

Denley, S.M., Jamieson, N.B. , McCall, P., Oien, K.C.S. , Morton, J.P. , Carter, C.R., Edwards, J. and McKay, C.J. (2013) Activation of the IL-6R/Jak/Stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Surgery, 17(5), pp. 887-898. (doi:10.1007/s11605-013-2168-7)

Chang, D.K. et al. (2013) Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. Journal of Clinical Oncology, 31(10), pp. 1348-1356. (doi:10.1200/JCO.2012.46.8868) (PMID:23439753)

Steele, C.W., Jamieson, N.B. , Evans, T.R.J. , McKay, C.J., Sansom, O.J. , Morton, J. and Carter, C.R. (2013) Exploiting inflammation for therapeutic gain in pancreatic cancer. British Journal of Cancer, 108(5), pp. 997-1003. (doi:10.1038/bjc.2013.24)

Jamieson, N.B. , Chan, N.I.J., Foulis, A.K., Dickson, E.J., McKay, C.J. and Carter, C.R. (2013) The prognostic influence of resection margin clearance following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Surgery, (doi:10.1007/s11605-012-2131-z)

2012

Jamieson, N.B. , Mohamed, M., Oien, K.A. , Foulis, A.K., Dickson, E.J., Imrie, C.W., Carter, C.R., McKay, C.J. and McMillan, D.C. (2012) The relationship between tumor inflammatory cell infiltrate and outcome in patients with pancreatic ductal adenocarcinoma. Annals of Surgical Oncology, 19(11), pp. 3581-3590. (doi:10.1245/s10434-012-2370-y)

Dozynkiewicz, M.A. et al. (2012) Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Developmental Cell, 22(1), pp. 131-145. (doi:10.1016/j.devcel.2011.11.008)

Jamieson, N. B. , Morran, D. C., Morton, J. P., Ali, A., Dickson, E. J., Carter, C. R., Sansom, O. J. , Evans, T. R. J. , McKay, C. J. and Oien, K. A. (2012) MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clinical Cancer Research, 18(2), pp. 534-545. (doi:10.1158/1078-0432.CCR-11-0679)

2011

Steele, C.W., Oien, K.A. , McKay, C.J. and Jamieson, N.B. (2011) Clinical potential of microRNAs in pancreatic ductal adenocarcinoma. Pancreas, 40(8), pp. 1165-1171. (doi:10.1097/MPA.0b013e3182218ffb)

Kennedy, A.l. et al. (2011) Activation of the PIK3CA/AKT Pathway Suppresses Senescence Induced by an Activated RAS Oncogene to Promote Tumorigenesis. Molecular Cell, 42(1), pp. 36-49. (doi:10.1016/j.molcel.2011.02.020)

Jamieson, N.B., Foulis, A.K., Oien, K.A. , Dickson, E.J., Imrie, C.W., Carter, R. and McKay, C.J. (2011) Peripancreatic Fat Invasion Is an Independent Predictor of Poor Outcome Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 15(3), pp. 512-524. (doi:10.1007/s11605-010-1395-4)

Jamieson, N.B., Carter, C.R., McKay, C.J. and Oien, K.O. (2011) Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis. Clinical Cancer Research, 17(10), pp. 3316-3331. (doi:10.1158/1078-0432.CCR-10-3284)

Jamieson, N.B., Denley, S.M., Logue, J., MacKenzie, D.J., Foulis, A.K., Dickson, E.J., Imrie, C.W., Carter, R., McKay, C.J. and McMillan, D.J. (2011) A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Annals of Surgical Oncology, 18(8), pp. 2318-2328. (doi:10.1245/s10434-011-1560-3)

2010

Chandrabalan, V. et al. (2010) Preoperative determinants of the length of hospital stay in patients undergoing surgery for pancreatic cancer. Pancreas, 39(8), p. 1313. (doi:10.1097/MPA.0b013e3181f73ec0)

Morton, J.P. et al. (2010) Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 107(1), pp. 246-251. (doi:10.1073/pnas.0908428107)

Jamieson, N. B., Foulis, A. K., Oien, K. A. , Going, J. J., Glen, P., Dickson, E. J., Imrie, C. W., McKay, C. J. and Carter, R. (2010) Positive Mobilization Margins Alone Do Not Influence Survival Following Pancreatico-Duodenectomy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 251(6), pp. 1003-1010. (doi:10.1097/SLA.0b013e3181d77369)

Lafferty-Whyte, K. et al. (2010) Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma. BMC Genomics, 11(1), p. 532. (doi:10.1186/1471-2164-11-532)

Morton, J. et al. (2010) LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology, 139(2), 586-597.e6. (doi:10.1053/j.gastro.2010.04.055)

Morton, J.P. et al. (2010) Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Gastroenterology, 139(1), pp. 292-303. (doi:10.1053/j.gastro.2010.03.034)

Nitsche, C. J., Jamieson, N., Lerch, M. M. and Mayerle, J. V. (2010) Drug induced pancreatitis. Best Practice and Research: Clinical Gastroenterology, 24(2), pp. 143-155. (doi:10.1016/j.bpg.2010.02.002)

2009

Lafferty-Whyte, K., Cairney, C.J., Jamieson, N., Oien, K.A. and Keith, W.N. (2009) Pathway analysis of senescence-associated miRNA targets reveals common processes to different senescence induction mechanisms. Biochimica et Biophysica Acta: Molecular Basis of Disease, 1792(4), pp. 341-352. (doi:10.1016/j.bbadis.2009.02.003)

2008

Robertson, E., Austin, D., Jamieson, N. and Hogg, K. (2008) Balsalazide-induced myocarditis. International Journal of Cardiology, 130(3), E121-E122.

2006

Glen, P., Jamieson, N.B., McMillan, D.C. , Carter, R., Imrie, C.W. and Mckay, C.J. (2006) Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology, 6(5), pp. 450-453. (doi:10.1159/000094562)

2005

Jamieson, N.B., Glen, P., McMillan, D.C. , McKay, C.J., Foulis, A.K., Carter, R. and Imrie, C.W. (2005) Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. British Journal of Cancer, 92(1), pp. 21-23. (doi:10.1038/sj.bjc.6602305)

Singhal, A., Jamieson, N.B., Fewtrell, M., Deanfield, J., Lucas, A. and Sattar, N. (2005) Adiponectin predicts insulin resistance but not endothelial function in young, healthy adolescents. Journal of Clinical Endocrinology and Metabolism, 90(8), pp. 4615-4621. (doi:10.1210/jc.2005-0131)

2004

Jamieson, N.B., Brown, D.J.F., Wallace, A.M. and McMillan, D.C. (2004) Adiponectin and the systemic inflammatory response in weight-losing patients with non-small cell lung cancer. Cytokine, 27(2-3), pp. 90-92. (doi:10.1016/j.cyto.2004.03.017)

2003

Jamieson, N.B., McMillan, D.C. , Brown, D.J.F. and Wallace, A.M. (2003) Comparison of simple acid-ethanol precipitation with gel exclusion chromatography for measuring leptin binding in serum of normal subjects and cancer patients. Annals of Clinical Biochemistry, 40(2), pp. 185-187. (doi:10.1258/000456303763046157)

Ramsay, J.E., Jamieson, N.B., Greer, I.A. and Sattar, N. (2003) Paradoxical elevation in adiponectin concentrations in women with preeclampsia. Hypertension, 42(5), pp. 891-894. (doi:10.1161/01.HYP.0000095981.92542.F6)

This list was generated on Thu Dec 5 16:22:35 2019 GMT.
Number of items: 81.

Articles

Pulvirenti, A. et al. (2019) Multi-institutional development and external validation of a nomogram to predict recurrence after curative resection of pancreatic neuroendocrine tumors. Annals of Surgery, (doi:10.1097/SLA.0000000000003579) (PMID:31567347) (Early Online Publication)

Dreyer, S.B., Jamieson, N.B. , Morton, J.P. , Sansom, O.J. , Biankin, A.V. and Chang, D.K. (2019) Pancreatic cancer: from genome discovery to PRECISION-Panc. Clinical Oncology, (doi:10.1016/j.clon.2019.08.007) (PMID:31522943) (In Press)

Vennin, C. et al. (2019) CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nature Communications, 10, 3637. (doi:10.1038/s41467-019-10968-6) (PMID:31406163) (PMCID:PMC6691013)

Dreyer, S.B., Jamieson, N.B. , Cooke, S.L. , Valle, J.W., McKay, C.J., Biankin, A.V. and Chang, D.K. (2019) PRECISION-Panc: the next generation therapeutic development platform for pancreatic cancer. Clinical Oncology, (doi:10.1016/j.clon.2019.07.011) (PMID:31378449) (In Press)

Reader, C. S. et al. (2019) The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Journal of Pathology, (doi:10.1002/path.5320) (PMID:31259422) (Early Online Publication)

Seykora, T. F. et al. (2019) The beneficial effects of minimizing blood loss in pancreatoduodenectomy. Annals of Surgery, 270(1), pp. 147-157. (doi:10.1097/SLA.0000000000002714) (PMID:29489483)

Janssen, Q. P. et al. (2019) Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. Journal of the National Cancer Institute, (doi:10.1093/jnci/djz073) (PMID:31086963) (Early Online Publication)

Dreyer, S. B. et al. (2019) Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. Chinese Clinical Oncology, 8(2), 16. (doi:10.21037/cco.2019.04.06) (PMID:31070037)

Singh, G., Nahm, C. B., Jamieson, N. B. , Chua, T. C., Wong, S., Thoo, C., Mittal, A., Gill, A. J. and Samra, J. S. (2019) Management of post-pancreatectomy haemorrhage using resuscitative endovascular balloon occlusion of the aorta. Langenbeck's Archives of Surgery, 404(2), pp. 253-255. (doi:10.1007/s00423-019-01759-0) (PMID:30758668)

Strijker, M., Chen, J.W., Mungroop, T.H., Jamieson, N.B. , van Eijck, C.H., Steyerberg, E.W., Wilmink, J.W., Groot Koerkamp, B., van Laarhoven, H.W. and Besselink, M.G. (2019) Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer. British Journal of Surgery, 106(4), pp. 342-354. (doi:10.1002/bjs.11111) (PMID:30758855)

Maggino, L. et al. (2019) Identification of an optimal cut-off for drain fluid amylase on postoperative day 1 for predicting clinically relevant fistula after distal pancreatectomy. Annals of Surgery, 269(2), pp. 337-343. 28938266. (doi:10.1097/SLA.0000000000002532)

Nahm, C. B. et al. (2019) Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: a multi-institutional cohort study. European Journal of Surgical Oncology, 45(2), pp. 218-224. (doi:10.1016/j.ejso.2018.10.050) (PMID:30348604)

Moekotte, A. L. et al. (2019) Histopathologic predictors of survival and recurrence in resected ampullary adenocarcinoma. Annals of Surgery, (doi:10.1097/SLA.0000000000003177) (PMID:30628913) (Early Online Publication)

Ecker, B. L. et al. (2019) Risk factors and mitigation strategies for pancreatic fistula after distal pancreatectomy. Annals of Surgery, 269(1), pp. 143-149. (doi:10.1097/SLA.0000000000002491) (PMID:28857813)

Dreyer, S. B. et al. (2018) Precision oncology in surgery: patient selection for operable pancreatic cancer. Annals of Surgery, (doi:10.1097/SLA.0000000000003143) (PMID:30570546) (Early Online Publication)

Ecker, B. L. et al. (2018) Characterization and optimal management of high-risk pancreatic anastomoses during pancreatoduodenectomy. Annals of Surgery, 267(4), pp. 608-616. (doi:10.1097/SLA.0000000000002327) (PMID:28594741)

Dreyer, S.B., Jamieson, N.B. , Upstill-Goddard, R., Bailey, P.J. , McKay, C.J., Australian Pancreatic Cancer Genome Initiative, , Biankin, A.V. and Chang, D.K. (2018) Defining the molecular pathology of pancreatic body and tail adenocarcinom. British Journal of Surgery, 105(2), e183-e191. (doi:10.1002/bjs.10772) (PMID:29341146) (PMCID:PMC5817249)

Ecker, B. L. et al. (2018) Pancreatogastrostomy vs. pancreatojejunostomy: a risk-stratified analysis of 5316 pancreatoduodenectomies. Journal of Gastrointestinal Surgery, 22(1), pp. 68-76. (doi:10.1007/s11605-017-3547-2) (PMID:28840459)

Balachandran, V. P. et al. (2017) Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 551, pp. 512-516. (doi:10.1038/nature24462) (PMID:29132146)

Scarpa, A. et al. (2017) Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 550(7677), p. 548. (doi:10.1038/nature24026) (PMID:28953865)

Grose, D. et al. (2017) The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. Journal of Gastrointestinal Oncology, 8(4), pp. 683-695. (doi:10.21037/jgo.2017.04.01) (PMID:28890819) (PMCID:PMC5582039)

Johns, A. L. et al. (2017) Lost in translation: returning germline genetic results in genome-scale cancer research. Genome Medicine, 9, 41. (doi:10.1186/s13073-017-0430-4) (PMID:28454591) (PMCID:PMC5408494)

Scarpa, A. et al. (2017) Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 543(7643), pp. 65-71. (doi:10.1038/nature21063) (PMID:28199314)

Jamieson, N.B. and Maker, A.V. (2017) Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Therapy, 24(3), pp. 134-140. (doi:10.1038/cgt.2016.63) (PMID:27834354)

Humphris, J. L. et al. (2017) Hypermutation in pancreatic cancer. Gastroenterology, 152(1), 68-74.e2. (doi:10.1053/j.gastro.2016.09.060) (PMID:27856273)

Steele, C. W. et al. (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell, 29(6), pp. 832-845. (doi:10.1016/j.ccell.2016.04.014) (PMID:27265504) (PMCID:PMC4912354)

Palani Velu, L.K., McKay, C.J., Carter, C.R., McMillan, D.C. , Jamieson, N.B. and Dickson, E.J. (2016) Serum amylase and C-reactive protein in risk stratification of pancreas-specific complications after pancreaticoduodenectomy. British Journal of Surgery, 103(5), pp. 553-563. (doi:10.1002/bjs.10098) (PMID:26898605)

Bailey, P. et al. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531(7592), pp. 47-52. (doi:10.1038/nature16965) (PMID:26909576)

Gingras, M.-C. et al. (2016) Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation. Cell Reports, 14(4), pp. 907-919. (doi:10.1016/j.celrep.2015.12.005) (PMID:26804919) (PMCID:PMC4982376)

Ali, A. et al. (2016) Investigating various thresholds as immunohistochemistry cutoffs for observer agreement. Applied Immunohistochemistry and Molecular Morphology, 25(9), pp. 599-608. (doi:10.1097/PAI.0000000000000357) (PMID:27093449)

Palani Velu, L., Chandrabalan, V., McMillan, D. , McKay, C., Carter, C. R., Jamieson, N. and Dickson, E. (2015) Routine drainage after pancreaticoduodenectomy. Annals of Surgery, 262(6), e107. (doi:10.1097/sla.0000000000000758) (PMID:24887980)

Jamieson, N. B. , Chang, D. K. and Biankin, A. V. (2015) Cancer genetics and implications for clinical management. Surgical Clinics of North America, 95(5), pp. 919-934. (doi:10.1016/j.suc.2015.05.003) (PMID:26315514)

Graham, J., Jamieson, N.B. , Rulach, R., Grimmond, S.M., Chang, D.K. and Biankin, A.V. (2015) Pancreatic cancer genomics: where can the science take us? Clinical Genetics, 88(3), pp. 213-219. (doi:10.1111/cge.12536) (PMID:25388820)

Palani Velu, L. K., Steele, C. W. , Dickson, E., Carter, C. R., McKay, C. J., Horgan, P. G. , McMillan, D. C. and Jamieson, N. B. (2015) RE:nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. Journal of the National Cancer Institute, 107(9), djv204. (doi:10.1093/jnci/djv204) (PMID:26251329)

Frampton, A. E. et al. (2015) microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: a meta-analysis. European Journal of Cancer, 51(11), pp. 1389-1404. (doi:10.1016/j.ejca.2015.04.006) (PMID:26002251)

McGlynn, L. M., McCluney, S., Jamieson, N. B. , Thomson, J., MacDonald, A. I., Oien, K. , Dickson, E. J., Carter, C. R., McKay, C. J. and Shiels, P. G. (2015) SIRT3 & SIRT7: potential novel biomarkers for determining outcome in pancreatic cancer patients. PLoS ONE, 10(6), e0131344. (doi:10.1371/journal.pone.0131344) (PMID:26121130) (PMCID:PMC4487247)

Solaini, L., Jamieson, N.B. , Metcalfe, M., Abu Hilal, M., Soonawalla, Z., Davidson, B.R., McKay, C. and Kocher, H.M. (2015) Outcome after surgical resection for duodenal adenocarcinoma in the UK. British Journal of Surgery, 102(6), pp. 676-681. (doi:10.1002/bjs.9791) (PMID:25776995)

Waddell, N. et al. (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518(7540), pp. 495-501. (doi:10.1038/nature14169) (PMID:25719666) (PMCID:PMC4523082)

Maker, A. V., Carrara, S., Jamieson, N. B. , Pelaez-Luna, M., Lennon, A. M., Dal Molin, M., Scarpa, A., Frulloni, L. and Brugge, W. R. (2015) Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: A critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. Journal of the American College of Surgeons, 220(2), pp. 243-253. (doi:10.1016/j.jamcollsurg.2014.11.001) (PMID:25592469) (PMCID:PMC4304635)

Rainero, E., Howe, J. D., Caswell, P. T., Jamieson, N. B. , Anderson, K., Critchley, D. R., Machesky, L. and Norman, J. C. (2015) Ligand-occupied integrin internalization links nutrient signaling to invasive migration. Cell Reports, 10(3), pp. 398-413. (doi:10.1016/j.celrep.2014.12.037)

Miller, B. W. et al. (2015) Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine, 7, pp. 1063-1076. (doi:10.15252/emmm.201404827) (PMID:26077591) (PMCID:PMC4551344)

Lunardi, S. et al. (2014) IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. Oncotarget, 5(22), pp. 11064-11080. (doi:10.18632/oncotarget.2519) (PMID:25415223) (PMCID:PMC4294325)

Morran, D. C. et al. (2014) Targeting mTOR dependency in pancreatic cancer. Gut, 63(9), pp. 1481-1489. (doi:10.1136/gutjnl-2013-306202) (PMID:24717934) (PMCID:PMC4145424)

Hamilton, G. et al. (2014) AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget, 5(15), pp. 6142-6167. (doi:10.18632/oncotarget.2178) (PMID:25071014) (PMCID:PMC4171619)

Palani Velu, L. K., Chandrabalan, V. V., Jabbar, S., McMillan, D. C. , McKay, C. J., Carter, C. R., Jamieson, N. B. and Dickson, E. J. (2014) Serum amylase on the night of surgery predicts clinically significant pancreatic fistula after pancreaticoduodenectomy. HPB, 16(7), pp. 610-619. (doi:10.1111/hpb.12184) (PMID:24246024)

Jamieson, N. B. , Chang, D. K. , Grimmond, S. M. and Biankin, A. V. (2014) Can we move towards personalised pancreatic cancer therapy? Expert Review of Gastroenterology and Hepatology, 8(4), pp. 335-338. (doi:10.1586/17474124.2014.893820) (PMID:24702631)

Li, A. et al. (2014) Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. Gastroenterology, 146(5), 1386-1396.e17. (doi:10.1053/j.gastro.2014.01.046)

Frampton, A. E., Giovannetti, E., Jamieson, N. B. , Krell, J., Gall, T. M.H., Stebbing, J., Jiao, L. R. and Castellano, L. (2014) A microRNA meta-signature for pancreatic ductal adenocarcinoma. Expert Review of Molecular Diagnostics, 14(3), pp. 267-271. (doi:10.1586/14737159.2014.893192)

Roxburgh, C.S. et al. (2014) A national survey of attitudes to research in Scottish General Surgery Trainees. Scottish Medical Journal, 59(1), pp. 9-15. (doi:10.1177/0036933013518142) (PMID:24434857)

Ali, A. et al. (2014) Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel. BMC Clinical Pathology, 14, p. 35. (doi:10.1186/1472-6890-14-35)

Chang, D. K. , Jamieson, N. B. , Scarpa, A., McKay, C. J. and Biankin, A. V. (2013) Reply to G.F. Arroyo. Journal of Clinical Oncology, 31(30), pp. 3843-3844. (doi:10.1200/JCO.2013.51.3176) (PMID:24043730)

Denley, S.M., Jamieson, N.B. , McCall, P., Oien, K.C.S. , Morton, J.P. , Carter, C.R., Edwards, J. and McKay, C.J. (2013) Activation of the IL-6R/Jak/Stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Surgery, 17(5), pp. 887-898. (doi:10.1007/s11605-013-2168-7)

Chang, D.K. et al. (2013) Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. Journal of Clinical Oncology, 31(10), pp. 1348-1356. (doi:10.1200/JCO.2012.46.8868) (PMID:23439753)

Steele, C.W., Jamieson, N.B. , Evans, T.R.J. , McKay, C.J., Sansom, O.J. , Morton, J. and Carter, C.R. (2013) Exploiting inflammation for therapeutic gain in pancreatic cancer. British Journal of Cancer, 108(5), pp. 997-1003. (doi:10.1038/bjc.2013.24)

Jamieson, N.B. , Chan, N.I.J., Foulis, A.K., Dickson, E.J., McKay, C.J. and Carter, C.R. (2013) The prognostic influence of resection margin clearance following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Surgery, (doi:10.1007/s11605-012-2131-z)

Jamieson, N.B. , Mohamed, M., Oien, K.A. , Foulis, A.K., Dickson, E.J., Imrie, C.W., Carter, C.R., McKay, C.J. and McMillan, D.C. (2012) The relationship between tumor inflammatory cell infiltrate and outcome in patients with pancreatic ductal adenocarcinoma. Annals of Surgical Oncology, 19(11), pp. 3581-3590. (doi:10.1245/s10434-012-2370-y)

Dozynkiewicz, M.A. et al. (2012) Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Developmental Cell, 22(1), pp. 131-145. (doi:10.1016/j.devcel.2011.11.008)

Jamieson, N. B. , Morran, D. C., Morton, J. P., Ali, A., Dickson, E. J., Carter, C. R., Sansom, O. J. , Evans, T. R. J. , McKay, C. J. and Oien, K. A. (2012) MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clinical Cancer Research, 18(2), pp. 534-545. (doi:10.1158/1078-0432.CCR-11-0679)

Steele, C.W., Oien, K.A. , McKay, C.J. and Jamieson, N.B. (2011) Clinical potential of microRNAs in pancreatic ductal adenocarcinoma. Pancreas, 40(8), pp. 1165-1171. (doi:10.1097/MPA.0b013e3182218ffb)

Kennedy, A.l. et al. (2011) Activation of the PIK3CA/AKT Pathway Suppresses Senescence Induced by an Activated RAS Oncogene to Promote Tumorigenesis. Molecular Cell, 42(1), pp. 36-49. (doi:10.1016/j.molcel.2011.02.020)

Jamieson, N.B., Foulis, A.K., Oien, K.A. , Dickson, E.J., Imrie, C.W., Carter, R. and McKay, C.J. (2011) Peripancreatic Fat Invasion Is an Independent Predictor of Poor Outcome Following Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 15(3), pp. 512-524. (doi:10.1007/s11605-010-1395-4)

Jamieson, N.B., Carter, C.R., McKay, C.J. and Oien, K.O. (2011) Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis. Clinical Cancer Research, 17(10), pp. 3316-3331. (doi:10.1158/1078-0432.CCR-10-3284)

Jamieson, N.B., Denley, S.M., Logue, J., MacKenzie, D.J., Foulis, A.K., Dickson, E.J., Imrie, C.W., Carter, R., McKay, C.J. and McMillan, D.J. (2011) A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Annals of Surgical Oncology, 18(8), pp. 2318-2328. (doi:10.1245/s10434-011-1560-3)

Chandrabalan, V. et al. (2010) Preoperative determinants of the length of hospital stay in patients undergoing surgery for pancreatic cancer. Pancreas, 39(8), p. 1313. (doi:10.1097/MPA.0b013e3181f73ec0)

Morton, J.P. et al. (2010) Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 107(1), pp. 246-251. (doi:10.1073/pnas.0908428107)

Jamieson, N. B., Foulis, A. K., Oien, K. A. , Going, J. J., Glen, P., Dickson, E. J., Imrie, C. W., McKay, C. J. and Carter, R. (2010) Positive Mobilization Margins Alone Do Not Influence Survival Following Pancreatico-Duodenectomy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 251(6), pp. 1003-1010. (doi:10.1097/SLA.0b013e3181d77369)

Lafferty-Whyte, K. et al. (2010) Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma. BMC Genomics, 11(1), p. 532. (doi:10.1186/1471-2164-11-532)

Morton, J. et al. (2010) LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology, 139(2), 586-597.e6. (doi:10.1053/j.gastro.2010.04.055)

Morton, J.P. et al. (2010) Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Gastroenterology, 139(1), pp. 292-303. (doi:10.1053/j.gastro.2010.03.034)

Nitsche, C. J., Jamieson, N., Lerch, M. M. and Mayerle, J. V. (2010) Drug induced pancreatitis. Best Practice and Research: Clinical Gastroenterology, 24(2), pp. 143-155. (doi:10.1016/j.bpg.2010.02.002)

Lafferty-Whyte, K., Cairney, C.J., Jamieson, N., Oien, K.A. and Keith, W.N. (2009) Pathway analysis of senescence-associated miRNA targets reveals common processes to different senescence induction mechanisms. Biochimica et Biophysica Acta: Molecular Basis of Disease, 1792(4), pp. 341-352. (doi:10.1016/j.bbadis.2009.02.003)

Robertson, E., Austin, D., Jamieson, N. and Hogg, K. (2008) Balsalazide-induced myocarditis. International Journal of Cardiology, 130(3), E121-E122.

Glen, P., Jamieson, N.B., McMillan, D.C. , Carter, R., Imrie, C.W. and Mckay, C.J. (2006) Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology, 6(5), pp. 450-453. (doi:10.1159/000094562)

Jamieson, N.B., Glen, P., McMillan, D.C. , McKay, C.J., Foulis, A.K., Carter, R. and Imrie, C.W. (2005) Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. British Journal of Cancer, 92(1), pp. 21-23. (doi:10.1038/sj.bjc.6602305)

Singhal, A., Jamieson, N.B., Fewtrell, M., Deanfield, J., Lucas, A. and Sattar, N. (2005) Adiponectin predicts insulin resistance but not endothelial function in young, healthy adolescents. Journal of Clinical Endocrinology and Metabolism, 90(8), pp. 4615-4621. (doi:10.1210/jc.2005-0131)

Jamieson, N.B., Brown, D.J.F., Wallace, A.M. and McMillan, D.C. (2004) Adiponectin and the systemic inflammatory response in weight-losing patients with non-small cell lung cancer. Cytokine, 27(2-3), pp. 90-92. (doi:10.1016/j.cyto.2004.03.017)

Jamieson, N.B., McMillan, D.C. , Brown, D.J.F. and Wallace, A.M. (2003) Comparison of simple acid-ethanol precipitation with gel exclusion chromatography for measuring leptin binding in serum of normal subjects and cancer patients. Annals of Clinical Biochemistry, 40(2), pp. 185-187. (doi:10.1258/000456303763046157)

Ramsay, J.E., Jamieson, N.B., Greer, I.A. and Sattar, N. (2003) Paradoxical elevation in adiponectin concentrations in women with preeclampsia. Hypertension, 42(5), pp. 891-894. (doi:10.1161/01.HYP.0000095981.92542.F6)

Book Sections

Steele, C. W., Jamieson, N. B. and Carter, C. R. (2014) Inflammatory dysregulation and cancer: From molecular mechanisms to therapeutic opportunities. In: Wondrak, G. T. (ed.) Stress Response Pathways in Cancer. Springer, pp. 375-395. ISBN 9789401794206 (doi:10.1007/978-94-017-9421-3_17)

Chang, D. K. , Jamieson, N. B. , Grimmond, S. M. and Biankin, A. V. (2014) Stratified medicine for pancreatic cancer. In: Padmanabhan, S. (ed.) Handbook of Pharmacogenomics and Stratified Medicine. Elsevier, pp. 807-814. ISBN 9780123868824 (doi:10.1016/B978-0-12-386882-4.00034-7)

Jamieson, N. B. , Grimmond, S. M., Biankin, A. V. and Chang, D. K. (2014) Pancreatic cancer: Challenges for therapeutic development. In: Scarlett, C. J. and Vuong, Q. V. (eds.) Plant Bioactive Compounds for Pancreatic Cancer Prevention and Treatment. Nova Science, pp. 1-28. ISBN 9781634633246

This list was generated on Thu Dec 5 16:22:35 2019 GMT.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • COMBINATION THERAPIES TARGETING IMMUNE EVASION IN PANCREATIC CANCER
    Cancer Research UK
    2018 - 2023
     
  • Using preoperative pancreatic endoscopic ultrasound to enable precision medicine for the management of pancreatic cancer
    Pancreatic Cancer Research Fund
    2015 - 2017
     
  • NcRNA Biomarkers In Pancreaticobiliary Malignancy - Implications For Therapy
    Academy of Medical Sciences
    2014 - 2015